p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes

Haematologica

Volumn 95, Issue 11, 2010, Pages 1964-1968

  Frisan, Emilie ^a,b,d   Pawlikowska, Patrycja ^a,b   Pierre Eugène, Cecile ^a,b,c   Viallon, Vivian ^d,e   Gibault, Laure ^d,e   Park, Sophie ^a,b,d,e   Mayeux, Patrick ^a,b   Dreyfus, François ^a,b,d,e   Porteu, Françoise ^a,b   Fontenay, Michaëla ^a,b,c,d  

^a INSTITUT COCHIN   (France)

^b CNRS   (France)

^c HÔTEL DIEU   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e Institut Cochin   (France)

Author keywords

Erythropoiesis stimulating agents; MAPkinase; Myelodysplastic syndromes; Red cells

Indexed keywords

CD45 ANTIGEN; CD71 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

5Q- SYNDROME; AGED; ARTICLE; BURST FORMING UNIT E; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMING UNIT E; CONTROLLED STUDY; DRUG RESPONSE; ERYTHROBLAST; ERYTHROCYTE TRANSFUSION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PREDICTION; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CELL PROLIFERATION; CELLS, CULTURED; ERYTHROBLASTS; ERYTHROPOIESIS; ERYTHROPOIETIN; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEMATINICS; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYELODYSPLASTIC SYNDROMES;

EID: 78149250055     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.024349     Document Type: Article

References (22)

1. Hellström-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol. 1995;89(1):67-71.
2. Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood. 1996;87(10):4076-81.
3. Hellström-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood. 1998;92(1):68-75.
4. Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, et al. GFM group (Groupe Francophone des Myélodysplasies). Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood. 2008;111(2):574-82.
5. Jädersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM, et al. Erythropoietin and granulocytecolony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008;26(21):3607-13.
6. Mantovani L, Lentini G, Hentschel B, Wickramanayake PD, Loeffler M, Diehl V, et al. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br J Haematol. 2000;109(2):367-75.
7. Hellström-Lindberg E, Negrin R, Stein R, Krantz S, Lindberg G, Vardiman J, et al. Erythroid response to treatment with GCSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol. 1997;99(2):344-51.
8. Remacha AF, Arrizabalaga B, Villegas A, Manteiga R, Calvo T, Julià A, et al. Erythropoietin plus granulocyte colonystimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group. Haematologica. 1999;84(12):1058-64.
9. Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, Quarré MC, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood. 2004;104(2):321-7.
10. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, et al. Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120(6):1037-46.
11. Cheson BD, Greenberg PL, Bennett JM, Löwenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108(2):419-25.
12. Claessens YE, Bouscary D, Dupont JM, Picard F, Melle J, Gisselbrecht S, et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood. 2002;99 (5):1594-601.
13. Bardet V, Tamburini J, Ifrah N, Dreyfus F, Mayeux P, Bouscary D, et al. Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry. Haematologica. 2006;91(6):757-64.
14. Hanley JA and McNeil BJ. A method of comparing the areas under the Receiver Operating Curves derived from the same samples. Radiology 1983;148(3):839-43.
15. Stasi R, Brunetti M, Bussa S, Conforti M, Di Giulio C, Crescenzi A, et al. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes. Clin Cancer Res 1997;3(5):733-9.
16. Kolbus A, Pilat S, Husak Z, Deiner EM, Stengl G, Beug H, et al. Raf-1 antagonizes erythroid differentiation by restraining caspase activation. J Exp Med. 2002;196(10):1347-53.
17. Dazy S, Damiola F, Parisey N, Beug H, Gandrillon O. The MEK-1/ERKs signaling pathway is differentially involved in the self-renewal of early and late avian erythroid progenitor cells. Oncogene. 2003;22(58):9205-16.
18. Ricciardi MR, McQueen T, Chism D, Milella M, Estey E, Kaldjian E, et al. Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia. 2005;19(9): 1543-9.
19. Lunghi P, Tabilio A, Pinelli S, Valmadre G, Ridolo E, Albertini R, et al. Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts. Hematol J. 2001;2(2):70-80.
20. Tamburini J, Elie C, Bardet V, Chapuis N, Park S, Broët P, et al. Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood. 2007;110(3):1025-8.
21. Gregorj C, Ricciardi MR, Petrucci MT, Scerpa MC, De Cave F, Fazi P, et al; GIMEMA Acute Leukemia Working Party. ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood. 2007;109(12):5473-6.
22. Westers TM, Alhan C, Chalumeau MED, van der Vorst MJDL, Eeltink C, Ossenkoppele GJ, et al. Aberrant immunophenotype of blasts in myelodysplasric syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. Blood 2010;115(9):1779-84.